NORTH CHICAGO, Ill. – Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients may benefit from safe and efficient outpatient monitoring of epcoritamab, according to revised results from the Phase 2 EPCORE® NHL-6 clinical trial announced by AbbVie today. According to the results, which were presented at the 13th Society of Hematologic Oncology (SOHO) Annual Meeting, this new T-cell-engaging bispecific antibody may provide patients with a more practical treatment choice, hence expanding access to care, especially in community settings.
The study demonstrated that epcoritamab can be administered on an outpatient basis. An overwhelming 92% of the 88 patients who got the treatment’s first complete dose were under outpatient monitoring. The frequency of adverse effects, including immune cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS), was in line with other research. 40.2% of patients experienced CRS, which was mostly low-grade and resolved in a median of two days without requiring treatment to be stopped. In a similar vein, 7.6% of patients experienced ICANS, which was primarily low-grade and went away in a median of three days without requiring medication withdrawal.
Read More: AbbVie Reports Breakthrough Results for RINVOQ® (Upadacitinib) in Alopecia Areata Treatment
Additionally, the trial showed encouraging efficacy. The complete response (CR) rate was 47.6% and the overall response rate (ORR) was 64.3% in patients who had only received one previous line of therapy. The ORR and CR rates for patients who had received two or more lines of therapy before were 60.0% and 38.0%, respectively.
The most prevalent kind of non-Hodgkin’s lymphoma is DLBCL, and in many cases, the cancer either recurs or develops resistance to therapy. The purpose of the 92-patient EPCORE® NHL-6 trial was to evaluate the safety of epcoritamab administered as an outpatient procedure.
Read More: AbbVie Enters Into the Obesity Drug Market With a License Agreement
Genmab and AbbVie collaborated to create the IgG1-bispecific antibody epcoritamab. It is applied subcutaneously and functions by activating T-cells and cells that express CD20, which results in the destruction of the malignant cells by T-cells.
For the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, including DLBCL resulting from indolent lymphoma, and high-grade B-cell lymphoma following two or more lines of systemic therapy, the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp). The FDA’s Accelerated designation program awarded this designation based on response durability and response rate. A confirmatory trial may be required to verify and describe the clinical benefit before this indication can continue to be approved.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
